Increasing incidence of nosocomialChryseobacterium indologenes infections in Taiwan

  • P. R. Hsueh
  • L. J. Teng
  • P. C. Yang
  • S. W. Ho
  • W. C. Hsieh
  • K. T. Luh


To understand the clinical features, antimicrobial therapy, and epidemiology ofChryseobacterium indologenes infections, the medical records of 36 patients with nosocomialChryseobacterium indologenes infections seen over a three-year period at National Taiwan University Hospital were reviewed. The 36 isolates recovered from these patients were studied by molecular typing and determination of antimicrobial susceptibility patterns. Nine patients had underlying neoplastic diseases, seven had diabetes mellitus, five had burn wounds, and four had uremia. The clinical syndrome included ten patients with intraabdominal infections, nine with wound sepsis, six with intravascular catheter-related bacteremia, and four with ventilator-associated pneumonia. Thirteen patients had monomicrobial bacteremia, and four had polymicrobial bacteremia. Nineteen patients (53%) developed infections associated with various indwelling devices. The deaths of five patients (14%) were directly attributable to infection withChryseobacterium indologenes. All isolates recovered showed a wide range of resistance to commonly used antimicrobial agents. The random amplified polymorphic DNA (RAPD) patterns of the isolates differed from each other, indicating the absence of epidemiological relatedness among these isolates. Nosocomial infection caused by multiresistantChryseobacterium indologenes appears to be an emerging problem in Taiwan and should be studied further.


Antimicrobial Agent Nosocomial Infection Moxalactam Clinical Infectious Disease Pyomyositis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vandamme P, Bernardet JF, Segers P, Kersters K, Holmes B: New perspectives in the classification of the flavobacteria: description ofChryseobacterium gen. nov.,Bergeyella gen. nov., andEmpedobacter nom. rev. International Journal of Systematic Bacteriology 1994, 44: 827–831.CrossRefGoogle Scholar
  2. 2.
    von Graevenitz A:Acinetobacter, Alcaligenes, Moraxella, and other nonfermentative gram-negative bacteria. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (ed): Manual of clinical microbiology. American Society for Microbiology, Washington DC, 1995, p. 520–532.Google Scholar
  3. 3.
    Stamm WE, Colella JJ, Anderson RL, Dixon RE: Indwelling arterial catheters as a source of nosocomial bacteremia: an outbreak caused byFlavobacterium species. New England Journal of Medicine 1975, 292: 1099–1102.PubMedCrossRefGoogle Scholar
  4. 4.
    Pedersen MM, Marso E, Pickett MJ: Nonfermentative bacilli associated with man: III. Pathogenecity and antibiotic susceptibility. American Journal of Clinical Pathology 1970, 54: 178–192.PubMedGoogle Scholar
  5. 5.
    Sader HS, Jones RN, Pfaller MA: Relapse of catheter-relatedFlavobacterium meningosepticum bacteremia demonstrated by DNA macrorestriction analysis. Clinical Infectious Diseases 1995, 21: 997–1000.PubMedGoogle Scholar
  6. 6.
    Sheridan RI, Ryan CM, Pasternack MS, Weber JM, Tompkins RG: Flavobacterial sepsis in massively burned pediatric patients. Clinical Infectious Diseases 1993, 17: 185–187.PubMedGoogle Scholar
  7. 7.
    Ratner H:Flavobacterium meningosepticum. Infection Control 1984, 5: 237–239.PubMedGoogle Scholar
  8. 8.
    Bruun B, Jensen ET, Lundstrom K, Andersen GE:Flavobacterium meningosepticum infections in a neonatal ward. European Journal of Clinical Microbiology & Infectious Diseases 1989, 8: 509–514.CrossRefGoogle Scholar
  9. 9.
    Siegman-Igra Y, Schwartz D, Soferman G, Konforti N:Flavobacterium group llb bacteremia: report of a case and review ofFlavobacterium infections. Microbiology and Immunology 1987, 176: 103–111.Google Scholar
  10. 10.
    Yabuuchi E, Kaneko T, Yano I, Moss CW, Miyoshi N:Sphingobacterium gen. nov.,Sphingobacterium spiritivorum comb. nov.,Sphingobacterium multivorum comb. nov.,Sphingobacterium mizutae sp. nov., andFlavobacterium indologenes sp. nov.: glucose-nonfermenting, gram-negative rods in CDC group llk-2 and llb. International Journal of Systematic Bacteriology 1983, 33: 580–598.Google Scholar
  11. 11.
    Yabuuchi E, Hashimoto Y, Ezaki T, Ido Y, Takeuchi N: Genotypic and phenotypic differentiation ofFlavobacterium indologenes fromFlavobacterium gleum. Microbiology and Immunology 1990, 34: 73–76.PubMedGoogle Scholar
  12. 12.
    Bonten MJM, van Tiel FH, van der Geest S, Smeets HGW, Stobberingh EE, Gaillard CA: Topical antimicrobial prophylaxis of nosocomial pneumonia in mechanically ventilated patients: microbiological observation. Infection 1993, 21: 137–139.PubMedCrossRefGoogle Scholar
  13. 13.
    Hsueh PR, Teng LJ, Ho SW, Hsieh WC, Luh KT: Clinical and microbiological characteristics ofFlavobacterium indologenes infections associated with indwelling devices. Journal of Clinical Microbiology 1996, 34: 1908–1913.PubMedGoogle Scholar
  14. 14.
    Hsueh PR, Hsiue TR, Hsieh WC: Pyomyositis in intravenous drug abusers: report of a unique case and review of the literature. Clinical Infectious Diseases 1996, 22: 858–860.PubMedGoogle Scholar
  15. 15.
    Hsueh PR, Hsiue TR, Wu JJ, Teng LJ, Ho SW, Hsieh WC, Luh KT:Flavobacterium indologenes bacteremia: clinical and microbiological characteristics. Clinical Infectious Diseases 1996, 23: 550–555.PubMedGoogle Scholar
  16. 16.
    Pickett MJ: Methods for identification of flavobacteria. Journal of Clinical Microbiology 1989, 27: 2309–2315.PubMedGoogle Scholar
  17. 17.
    National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A2. NCCLS, Villanova, PA, 1993.Google Scholar
  18. 18.
    Dickinson GM, Bisno AL: Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devices. Antimicrobial Agents and Chemotherapy 1989, 33: 597–601.PubMedGoogle Scholar
  19. 19.
    Salata RA, Lederman MM, Shlaes DM, Jacobs MR, Eckstein E, Tweardy D, Toossi Z, Chmielewski R, Marino J, King CH, Graham RC, Ellner JJ: Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients. American Review of Respiratory Disease 1987, 135: 426–432.PubMedGoogle Scholar
  20. 20.
    Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992, 101: 1644–1655.PubMedGoogle Scholar
  21. 21.
    Holmes BR, Owen RJ, Steigerwalt AG, Brenner DJ:Flavobacterium gleum, a new species found in human clinical specimens. International Journal of Systematic Bacteriology 1984, 34: 21–25.CrossRefGoogle Scholar
  22. 22.
    Verhasselt B, Claey G, Elaichouni A, Verschraegen G, Laureys G, Vaneechoutte M: Case of recurrentFlavimonas oryzihabitans bacteremia associated with an implanted central venous catheter (Port-A-Cath): assessment of clonality by arbitrarily primed PCR. Journal of Clinical Microbiology 1995, 33: 3047–3048.PubMedGoogle Scholar
  23. 23.
    Coyle-Gilchrist MM, Crewe P, Roberts G:Flavobacterium meningosepticum in the hospital environment. Journal of Clinical Pathology 1976, 29: 824–826.PubMedGoogle Scholar
  24. 24.
    Nathan P, Holder IA, MacMillan BG: Burn wounds: microbiology, local host defenses and current therapy. Critical Review of Clinical Laboratory Science 1983, 4: 61–78.CrossRefGoogle Scholar
  25. 25.
    Pollack M:Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R (ed): Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone, New York, 1995, p. 1980–2003.Google Scholar
  26. 26.
    Aber RC, Wennersten C, Moellering RC Jr: Antimicrobial susceptibility of flavobacteria. Antimicrobial Agents and Chemotherapy 1978, 14: 483–487.PubMedGoogle Scholar
  27. 27.
    Strandberg DA, Jorgensen JH, Drutz DJ: Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli. Antimicrobial Agents and Chemotherapy 1983, 24: 282–286.PubMedGoogle Scholar
  28. 28.
    Jorgensen JH, Maher LA, Howell AW: Activity of meropenem against antibiotic-resistant or infrequently encountered gram-negative bacilli. Antimicrobial Agents and Chemotherapy 1991, 35: 2410–2414.PubMedGoogle Scholar
  29. 29.
    Raimondi A, Moosdeen FF, Williams JD: Antibiotic resistance pattern ofFlavobacterium meningosepticum. European Journal of Clinical Microbiology & Infectious Diseases 1986, 5: 461–463.CrossRefGoogle Scholar
  30. 30.
    von Graevenitz A, Grehn M: Susceptibility studies onFlavobacterium ll-b. FEMS Microbiology Letters 1977, 2: 289–292.CrossRefGoogle Scholar

Copyright information

© MMV Medizin Verlag GmbH 1997

Authors and Affiliations

  • P. R. Hsueh
    • 1
    • 2
  • L. J. Teng
    • 1
    • 3
  • P. C. Yang
    • 2
  • S. W. Ho
    • 1
    • 3
  • W. C. Hsieh
    • 2
  • K. T. Luh
    • 1
    • 2
  1. 1.Department of Laboratory MedicineNational Taiwan University HospitalTaipei 100Taiwan
  2. 2.Department of Internal MedicineNational Taiwan University HospitalTaipei 100Taiwan
  3. 3.School of Medical TechnologyNational Taiwan UniversityTaipeiTaiwan

Personalised recommendations